Trial no.:
|
PACTR201708002507912 |
Date of Approval:
|
09/08/2017 |
Trial Status:
|
Retrospective registration - This trial was registered after enrolment of the first participant |
|
TRIAL DESCRIPTION |
Public title
|
Role of bovine colostrum in the treatment of acute diarrhea in children |
Official scientific title |
Role of bovine colostrum in the treatment of acute diarrhea in children |
Brief summary describing the background
and objectives of the trial
|
Acute infectious diarrhea is inflammation of the gastrointestinal tract that involves the stomach and small intestine. This typically lasts three to five days and less than two weeks. Gastroenteritis can be due to infections by viruses, bacteria, parasites, and fungus. The most common cause is viruses. In children, rotavirus is the most common cause of severe disease. Transmission may occur due to eating improperly prepared foods, drinking contaminated water, or through close contact with an individual who is infected. Supportive therapy(appropriate diet, fluid therapy) should be considered for all patients suffering from diarrhea, while antimicrobials are not recommended as enteropathogens are often associated with self-limiting diarrhea. Numerous in vivo and in vitro studies have shown that Bovine Colostrum (BC) is beneficial in the prevention and treatment of infective gastroenteritis. The bioactive components of colostrum include: anti-microbial factors, immune stimulating peptides and growth factors. Anti-microbial factors provide passive immunity and protect against infections, especially during the first weeks of life. The aim of the present work is to study the role of bovine colostrum (Immuguard) in the treatment of acute diarrhea in children. |
Type of trial |
RCT |
Acronym (If the trial has an acronym then please provide) |
|
Disease(s) or condition(s) being studied |
Acute diarrhea in children,Infections and Infestations,Paediatrics |
Sub-Disease(s) or condition(s) being studied |
infectious diarrhea |
Purpose of the trial |
Treatment: Other |
Anticipated trial start date |
01/10/2016 |
Actual trial start date |
15/11/2016 |
Anticipated date of last follow up |
01/03/2017 |
Actual Last follow-up date |
05/04/2017 |
Anticipated target sample size (number of participants) |
138 |
Actual target sample size (number of participants) |
160 |
Recruitment status |
Completed |
Publication URL |
|
|